Agios Pharm - Asset Resilience Ratio
Agios Pharm (AGIO) has an Asset Resilience Ratio of 52.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Agios Pharm's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Agios Pharm's Asset Resilience Ratio has changed over time. See how leveraged is Agios Pharm's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Agios Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Agios Pharm.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $623.44 Million | 52.61% |
| Total Liquid Assets | $623.44 Million | 52.61% |
Asset Resilience Insights
- Very High Liquidity: Agios Pharm maintains exceptional liquid asset reserves at 52.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Agios Pharm Industry Peers by Asset Resilience Ratio
Compare Agios Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Agios Pharm (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Agios Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 58.99% | $765.29 Million | $1.30 Billion | +9.84pp |
| 2024-12-31 | 49.15% | $817.46 Million | $1.66 Billion | -24.34pp |
| 2023-12-31 | 73.49% | $688.72 Million | $937.12 Million | +21.52pp |
| 2022-12-31 | 51.98% | $643.86 Million | $1.24 Billion | -4.84pp |
| 2021-12-31 | 56.82% | $816.89 Million | $1.44 Billion | +4.59pp |
| 2020-12-31 | 52.23% | $445.49 Million | $852.95 Million | -2.10pp |
| 2019-12-31 | 54.33% | $483.95 Million | $890.74 Million | -5.64pp |
| 2018-12-31 | 59.97% | $514.80 Million | $858.46 Million | +7.69pp |
| 2017-12-31 | 52.28% | $321.21 Million | $614.40 Million | -9.19pp |
| 2016-12-31 | 61.47% | $380.56 Million | $619.09 Million | +3.09pp |
| 2015-12-31 | 58.38% | $245.24 Million | $420.06 Million | -8.31pp |
| 2014-12-31 | 66.69% | $328.03 Million | $491.90 Million | +19.37pp |
| 2013-12-31 | 47.32% | $95.21 Million | $201.21 Million | +20.55pp |
| 2012-12-31 | 26.77% | $36.68 Million | $137.01 Million | -4.86pp |
| 2011-12-31 | 31.63% | $61.51 Million | $194.47 Million | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more